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AN INVESTIGATION INTO THE TRANSCRIPTIONAL REGULATION OF 
TMIGD1 IN RENAL EPITHELIAL CELLS  
MARWA ALI  
ABSTRACT 
 Tumorigenesis is a complex process that begins with the accumulation of 
several aberrant gene mutations that often favor cell proliferation while 
antagonizing anti-proliferative signaling pathways. Tumor cells acquire 
additional genetic alterations, which allow them to change their cellular 
metabolism, promote angiogenesis, invade tissue, and metastasize. Together, the 
genetic changes that abrogate the function of tumor suppressors and promote 
oncogenesis are key to cellular transformation and tumorigenesis. A novel Ig 
domain-containing adhesion molecule (Ig-CAM), Transmembrane and 
Immunoglobulin (Ig) Domain-containing 1 (TMIGD1), was recently identified in 
our laboratory. TMIGD1 is expressed in renal epithelial cells and plays a 
protective role against oxidative cell injury. TMIGD1 expression is 
downregulated in human renal cancers. However, the mechanisms of 
downregulation of TMIGD1 in renal cancer have yet to be defined.   
In this study, we investigated the transcriptional regulation of TMIGD1 
using a green fluorescent protein (GFP) reporter assay. The proximal promoter of 
human TMIGD1 contains multiple CCAAT box sequences with the 
GGCCAATCT consensus, which are putative binding sites for the transcription 
factor CCAAT/Enhancer-binding protein (C/EBP!). This study demonstrates 
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that the transcriptionally active C/EBP!/LAP activates the TMIGD1 promoter, 
while the transcriptionally inactive C/EBP!/LIP inhibits TMIGD1 promoter 
activity. When the putative CCAAT box sequences are deleted from the TMIGD1 
promoter, C/EBP!/LAP no longer has a marked effect on the promoter activity. 
Through additional analysis, we show that several transcription factors and 
proteins that are commonly implicated in renal cancers, including pVHL, HIF1α, 
HIF2α, β-catenin, and APC, do not seem to have a noticeable effect on TMIGD1 
promoter activity. Collectively, the present study identifies C/EBP! as an 
important transcription factor in the transcriptional regulation of TMIGD1. 
Furthermore, the study suggests a possible role for C/EBP! in downregulation 
of TMIGD1 in renal cancer. 
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INTRODUCTION 
 
This year, it is expected that kidney and renal pelvis cancers will reach 
about 63,000 new cases, accounting for 14,400 deaths (Siegel, Miller, & Jemal, 
2017). Kidney and pelvic cancers are the sixth and tenth leading cancers in men 
and women respectively (Siegel et al., 2017). Renal cell carcinomas (RCCs) derive 
from renal tubule cells and account for nearly 90% of kidney cancer cases (Shaw, 
2016). There are several types of RCCs, each stemming from a different genetic 
mutation (Yap et al., 2015). These include clear cell renal-cell carcinoma, 
papillary renal-cell carcinoma, oncocytoma, chromophobe renal-cell carcinoma, 
and collecting-duct renal cell carcinoma (Yap et al., 2015). Though most RCCs 
occur sporadically, studies of the nearly 3% of RCCs that arise from inherited 
mutations have contributed most of the current understanding of the 
mechanisms of tumorigenesis in RCCs (Yap et al., 2015).  
 
Genetics of renal cancers 
Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary 
disease with an incidence of about 1/36000 that predisposes individuals to 
different types of tumors, including phaeochromocytomas, pancreatic 
neuroendocrine tumors, and clear cell renal cell carcinoma (Gossage, Eisen, & 
Maher, 2015; Latif et al., 1993).  Clear cell renal cell carcinomas, which make up 
80-90% of RCCs, are the most common of both sporadic and VHL disease related 
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renal cell carcinomas and both cases have demonstrated aberrations in loci on 
chromosome 3 (Gnarra et al., 1994; Yap et al., 2015). These loci were found to 
contain the VHL gene, which was later cloned, and it was also found that VHL is 
mutated in 57% of cases of sporadic clear-cell renal-cell carcinomas (Gnarra et al., 
1994; Latif et al., 1993). VHL’s distinct role in renal tumorigenesis was 
highlighted by observations that VHL mutations in other cancer types is 
uncommon (Gnarra et al., 1994). Additional observations by Gnarra et al. (1994) 
that localized and advanced tumors both exhibit VHL mutations, while 
advanced tumors are more likely to contain other genetic aberrations, such as 
p53 mutations, indicate that inactivating VHL mutations are key in the initiation 
of renal cancer development (Gnarra et al., 1994). A study looking at loss of 
heterozyosity (LOH) of VHL in patients with sporadic renal cell carcinoma, 
which was expected if VHL were a tumor suppressor, revealed that 98% of the 
samples had LOH (Gnarra et al., 1994). Furthermore, when the wild-type VHL 
gene is transfected into VHL-deficient renal cell carcinoma cell lines, cell 
proliferation and growth are reduced, while in VHL-null nude mice, wild-type 
VHL was able to reduce tumor formation (Chen et al., 1995; Iliopoulos, Kibel, 
Gray, & Kaelin, 1995). These studies highlight VHL’s role as a tumor suppressor 
gene.  
The role of pVHL, the protein product of the VHL gene, as a tumor 
suppressor lies chiefly in its ability to regulate the activity of the transcription 
factors hypoxia-inducible-factors 1α and 2α (HIF1α and HIF2α). pVHL can bind 
to Elongin B, Elongin C, and Cullin2 to form a complex which has ubiquitin 
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ligase activity (Banumathy & Cairns, 2010). Under normoxic (normal 
physiological oxygen level) conditions, pVHL, through contact with HIFα and 
within the ubiquitin ligase complex, targets HIFα for proteasomal degradation 
(Tanimoto, Makino, Pereira, & Poellinger, 2000). Yet in hypoxic (reduced or lack 
of oxygen) conditions or when there is a lack of functional pVHL, as in RCC, 
HIFα accumulates intracellularly, dimerizes with HIFβ in the nucleus, and binds 
to the hypoxia response element (HRE) on DNA to up-regulate pro-angiogenic 
factors, proliferation pathways, and glucose transport mechanisms (Figure 1) 
(Banumathy and Cairns 2010). In the nucleus, HIFα stimulates the expression of 
certain genes that promote tumorigenesis (Semenza, 2012). For example, HIFα 
leads to the expression of growth factors that function in an autocrine fashion to 
affect cell proliferation, the expression of glucose transporters, and genes that 
inhibit cell-cell contact and promote invasion (Semenza, 2012).  HIF1α and HIF2α 
do not have identical roles within the cell and in fact, it is believed that HIF1α 
plays a major role in affecting cellular metabolism and apoptosis while HIF2α 
affects proliferation and angiogenesis (Gossage et al., 2015).  
In addition to its role in HIFα degradation, pVHL also interacts with the 
Wnt signaling pathway through β-catenin (Banumathy & Cairns, 2010). The Wnt 
pathway plays a role in the control of cell proliferation, differentiation, and 
survival and is often up-regulated in cancers (Banumathy & Cairns, 2010; Barker 
& Clevers, 2006). The canonical Wnt signaling pathway results in the expression 
of pro-proliferation and differentiation genes by preventing degradation of the 
transcription factor β-catenin, thus allowing it to translocate to the nucleus and 
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act in concert with proteins from the LEF-TCF family to induce transcription 
(Figure 1) (Banumathy & Cairns, 2010; Barker & Clevers, 2006). Normally, β-
catenin is maintained at low levels in the cell by a group of proteins, called the 
“destruction complex ” which includes the protein APC (Barker & Clevers, 2006). 
This complex leads to β-catenin phosphorylation through the actions of the 
protein kinases CK1 and GSK3, an event which allows β-catenin to be recognized 
and ubiquitin-tagged for degradation (Figure 1) (Barker & Clevers, 2006). 
There is evidence that in addition to being targeted for degradation by the 
APC containing complex, β-catenin can also be degraded by the pVHL-CUL2-
ElonginB-ElonginC complex (Banumathy & Cairns, 2010). Co-
immunoprecipitation assays demonstrated a possible physical association 
between pVHL and β-catenin that is able to prevent β-catenin’s ability to carry 
out downstream signaling (Peruzzi, Athauda, & Bottaro, 2006). This suggests 
that perhaps the Wnt signaling pathway plays a role in renal tumorigenesis such 
that when pVHL is mutated, as is often the case in RCCs, there is an 
accumulation of β-catenin and an increase in the downstream effectors’ functions 
(Banumathy & Cairns, 2010). Additional studies have also found a link between 
VHL and β-catenin. Through ubiquitin ligase activity, the protein Jade-1, which 
is stabilized by pVHL, downregulates β-catenin (Chitalia et al., 2008). If pVHL is 
mutated, then Jade-1 levels decrease, resulting in the accumulation of β-catenin 
(Chitalia et al., 2008).  
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Figure 1: A Schematic of the effects of pVHL and APC on downstream targets. 
The image is a simplified schematic of the effects of pVHL and APC on their 
downstream effectors as well as the point of intersection of these two pathways, 
which lies at the degradation of β-catenin. The dark blue dots in the image above 
represent ubiquitination; the green lines represent pathways that lead to gene 
expression; the red lines represent pathways that lead to protein degradation.   
(Adapted from Barker & Clevers, 2006 and Gossage et al., 2015).   
 
The actions of tumor suppressor genes and oncogenes are key to the 
process of tumorigenesis. Cancer develops due to a cell’s accumulation of 
multiple mutations and genetic changes that allow it to escape normal controls 
on cell division and cell death and to eventually progress from a benign group of 
cells to a malignant cancer (Alberts et al., 2002a). The genetic changes that allow 
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cancer cells to thrive and transform include mutations that permit the cells to 
acquire certain characteristics, termed “hallmarks” by Hanahan and Weinberg, 
and include the ability to resist apoptosis, to ignore growth suppressors and 
continue proliferating, to induce angiogenesis, and eventually to become 
invasive and metastastatic (Hanahan & Weinberg, 2011). Oncogenes are the 
mutated form of proto-oncogenes, which are normal genes that when mutated or 
over-expressed can lead to pro-cancer cellular events (Alberts et al., 2002b; 
Hanahan & Weinberg, 2011). They may cause increased cell proliferation by 
inappropriately activating proliferative pathways or by inactivating negative 
feedback pathways that would otherwise prevent uncontrolled proliferation 
(Hanahan & Weinberg, 2011). Ras, a prototypical oncogene, is mutated in 30% of 
cancers (Adjei, 2001). Ras participates in signal transduction pathways and 
contains intrinsic GTPase activity, which is compromised when Ras is mutated 
(Cox & Der, 2010). Mutations in Ras significantly reduce Ras’s ability to interact 
with the Ras-GAP, thereby diminishing Ras’s ability to hydrolyze GTP to GDP 
and thus the protein remains in the active GTP-bound form (Cox & Der, 2010; 
Trahey & McCormick, 1987). Thus, its pro-proliferative signaling remains on, 
causing cell division to continue (Adjei, 2001). Ras’s role in inducing tumors has 
been demonstrated by several studies in animal models and include studies that 
link Ras mutations to tumors of the lung, mammary glands, and pancreas among 
others (Malumbres & Barbacid, 2003).  
Tumor–suppressors, on the other hand, normally prevent tumor 
formation by antagonizing or acting as inhibitors of cell proliferation and 
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tumorigenesis (Hanahan & Weinberg, 2011).  One of the most well-known tumor 
suppressors, p53, is mutated and inactivated in about 50% of human cancers; 
however, it normally behaves as a growth suppressor (Bieging, Mello, & Attardi, 
2014; Hanahan & Weinberg, 2011). Wild type p53 prevents cell cycle progression 
or may even induce apoptosis in conditions of intracellular or extracellular 
stressors, such as significant DNA damage (Bieging et al., 2014). In the presence 
of DNA damage, p53 levels increase and it is activated, thus p53 is able to 
overcome its repressor and promote transcription of its target genes, including 
p21 (Levine, 1997). p21 can then bind to cyclin-Cdk complexes and PCNA to 
inhibit cell cycle progression and DNA replication respectively (Levine, 1997). 
Evidence of p53’s role as a tumor suppressor includes findings in colon cancer 
cells that wild type p53 could reduce cell growth, while mutated p53 could not 
(Baker, Markowitz, Fearon, Willson, & Vogelstein, 1990). In addition, p53’s role 
as a tumor suppressor was demonstrated in animal studies of mice that are p53-
null, which developed spontaneous tumors with greater frequency than did mice 
that were heterozygous for the p53 inactivating mutation (Donehower et al., 
1992). As illustrated be the examples of Ras and p53, oncogenes and tumor 
suppressors may be capable of acting as transcription factors or otherwise affect 
transcription factor levels, and thus can regulate the expression of genes in 
processes that may ultimately lead to the malignant transformation of cells.  
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Role of C/EBP transcription factors in human cancers 
The importance of altered transcription factor expression levels in cancers 
is illustrated by the example of C/EBPβ. C/EBPβ, along with C/EBP", C/EBPγ, 
C/EBPδ, C/EBPε, and C/EBPς, is a member of the C/EBP family of basic leucine 
zipper transcription factors (Tsukada, Yoshida, Kominato, & Auron, 2011). The 
name “C/EBP” derives from studies of the first known C/EBP family member 
and described the ability of this transcription factor to bind to the CCAAT box 
promoter proximal element as well as several enhancers (Pulido-Salgado, Vidal-
Taboada, & Saura, 2015). It has been shown that in fact, the members of the 
C/EBP family can bind to several identified consensus sequences, including 
RTTGC•GYAAY, in which R represents a purine and Y represents a pyrimidine 
(Tsukada et al., 2011). The DNA-binding domain at the carboxyl terminus of 
these transcription factors allows them to bind to the DNA, while a transcription 
activation domain at the amino terminus interacts with transcriptional co-
activators (Tsukada et al. 2011). C/EBP family members can act as homodimers 
or heterodimers to affect cell proliferation, differentiation, survival, metabolism, 
and inflammation, as well as other functions (Ramji & Foka, 2002; Tsukada et al., 
2011).  
The gene that codes for the C/EBP! protein does not contain introns, yet 
there are three sub-isoforms of C/EBP! that are generated post-transcription 
during a translational mechanism which makes use of multiple start codons on 
the same mRNA (Tsukada et al., 2011). The three sub-isoforms are known as 
Liver-Activator Protein Star (LAP*), with a molecular weight of 38 kDa, Liver 
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Activating Protein (LAP), 35 kDa, and Liver Inactivating Protein (LIP), 20 kDa 
(Tsukada et al., 2011). While LAP* and LAP both contain the DNA-binding 
domain and the transactivation domain, LIP does not contain the 185 amino 
acids that constitute the transactivation domain (Bégay et al., 2015). Therefore, 
LIP can bind to the DNA, but cannot participate in protein-protein interactions 
and thus it acts as a dominant negative (Bégay et al., 2015; Tsukada et al., 2011). 
Though cells express both LIP and LAP isoforms simultaneously, an increase in 
the LIP: LAP ratio has been associated with several cancer types (Bégay et al., 
2015). When LIP was over expressed in transgenic mouse models and in 
mammary epithelial cells, evidence of increased abnormal cell proliferation was 
observed (Zahnow, Cardiff, Laucirica, Medina, & Rosen, 2001). Furthermore, 
studies of a knock-in mouse model that expresses LIP showed increased 
tumorigenesis in several tissues, including non-Hodgkin’s lymphoma, histiocytic 
sarcoma, and lung adenocarcinoma (Bégay et al., 2015).   
Several studies have specifically highlighted the possible role of the 
C/EBP family of transcription factors in renal cancer. First, a study of 44 RCC 
patient samples found that in many advanced cases, increased C/EBPβ activity 
and increased tumor invasiveness were linked (Oya, Horiguchi, Mizuno, 
Marumo, & Murai, 2003). It is believed that C/EBPβ may carry out this invasive 
function by increasing expression of enzymes called matrix metalloproteases that 
allow cells to digest the extracellular matrix (ECM) (Petrella & Vincenti, 2012). IL-
1β, a cytokine that is expressed at high levels in patients with advanced stage 
RCC, acts by modulating the level of C/EBPβ expression and thereby increasing 
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the expression of matrix metalloproteases (Petrella & Vincenti, 2012). The 
importance of C/EBPβ in IL-1β’s ability to stimulate ECM breakdown was 
highlighted when knockdown of C/EBPβ reduced cells’ ability to breakdown 
collagen in the ECM (Petrella & Vincenti, 2012). In addition, studies show that 
C/EBPα may also play a role in renal cell carcinoma. It was found that YY1, a 
transcription factor can be oncogenic and that is upregulated in RCCs, is able to 
suppress C/EBPα expression (Weng et al., 2014). Meanwhile, increases in 
C/EBPα was found to increase the expression of miRNA that could carry out 
tumor suppressor functions by repressing the YY1 transcription factor and 
blocking its tumorigenic effects (Weng et al., 2014). 
Given the many transcription factors that play a role in tumorigenesis, 
including C/EBP!, HIFα, and p53, an understanding of the normal interaction of 
specific transcription factors with a gene promoter is key to gaining an 
understanding of how transcription might be altered in certain cancers. Normal 
gene regulation at the level of transcription depends on chromatin structure, the 
structure of the gene promoter, RNA Polymerase II, and the presence of 
appropriate transcription factors. The promoter, a regulatory sequence found 
upstream of a gene, is made up of the core promoter as well as promoter 
proximal elements that help to control gene expression (Griffiths, Miller, Suzuki, 
Lewontin, & Gelbart, 2000). The core promoter is a region upstream of the 
transcription initiation site that is about 50-100 base pairs long (Roy & Singer, 
2015). It is the site where the pre-initiation complex forms in the steps to initiate 
transcription, bringing the general transcription factors and RNA polymerase II 
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together (Griffiths et al., 2000; Roy & Singer, 2015). The core promoter consists of 
several elements, including a sequence found 30 base pairs upstream of the 
transcription start site referred to as the TATA box (Griffiths et al., 2000; Roy & 
Singer, 2015). Other elements include the Inr, Downstream Promoter Element 
(DPE), the TFIIB recognition element (BRE), Downstream Core Element (DCE), 
and the TCT element (Roy & Singer, 2015). 
 In order for transcription to be activated, the general transcription factors 
must bind the core promoter and recruit RNA Polymerase II to the promoter 
(Alberts et al., 2002c; Roy & Singer, 2015). The TATA box, an element of the core 
promoter in many genes, functions as the site of binding for TFIID—a general 
transcription factor—which recruits the other general transcription factors 
designated TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH (Roy & Singer, 2015). The 
general transcription factor TFIIB recruits TFIIF and RNA Polymerase II to the 
promoter, while TFIIH is able to unwind the DNA in an ATP-dependent process 
and also contains a kinase domain that phosphorylates RNA polymerase II, 
allowing elongation to begin (Grünberg & Hahn, 2013; Roeder, 1996). The core 
promoter does not act alone, but in concert with promoter proximal elements, 
including the CCAAT box, GC rich region, enhancers, and silencers, and thus in 
addition to the general transcription factors RNA polymerase II requires other 
proteins, including transcriptional activators and repressors, that bind to these 
additional promoter elements in order to copy DNA into RNA (Alberts et al., 
2002c; Griffiths et al., 2000). The mechanisms that regulate gene expression are 
intricate, although the theme tends to be that the different DNA elements create 
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binding sites for transcription factors, co-factors, and RNA polymerase II binding 
in order to carry out the process of copying DNA into RNA. 
 
Role of cell adhesion molecule TMIGD1 in renal epithelial cells  
Transmembrane and immunoglobulin (Ig) domain-containing 1 
(TMIGD1) is a member of the IGPR-1 family of cell adhesion molecules and is 
expressed in kidney tubular epithelial cells (Arafa et al., 2015). It contains two 
extracellular immunoglobulin domains, a transmembrane domain, and a short 
intracellular domain (Arafa et al., 2015) (Figure 2). Cell aggregation assays 
indicated that TMIGD1 plays a role in cell-cell adhesion as HEK293 cells that 
expressed TMIGD1 showed increased aggregation when compared to HEK293 
cells that did not express TMIGD1 (Arafa et al., 2015). It is believed that TMIGD1 
facilitates cell-cell adhesion through the interaction of an immunoglobulin 
domain of one TMIGD1 molecule with an immunoglobulin domain of another 
TMIGD1 molecule, forming a dimer (Arafa et al., 2015).  In addition, HEK 293 
cells expressing TMIGD1 were shown to have reduced a cell proliferation rate, 
reduced migration, and altered actin filament organization when compared to 
cells that do not express TMIGD1 (Arafa et al., 2015). TMIGD1 was also found to 
have a protective role against oxidative damage in normal kidney epithelial cells 
(Arafa et al., 2015).  
Further studies in our laboratory indicated that TMIGD1 expression is 
downregulated in human renal cancers, suggesting a possible tumor suppressor 
function for TMIGD1 in human renal cancers (Meyer et al., 2017, unpublished 
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data not shown). Furthermore, bioinformatics analysis indicated that the 
TMIGD1 promoter contains multiple putative C/EBP! binding sites (Meyer et 
al., 2017, unpublished data not shown). Along with consideration of the role of 
C/EBP! in various human cancers, this prompted us to investigate the possible 
role of C/EBPβ in the regulation of TMIGD1 promoter activity. 
 
Figure 2: Schematic of TMIGD1. The schematic represents the structure of 
TMIGD1, which contains two extracellular immunoglobulin domains (purple 
circles), a transmembrane domain (blue rectangle), and a short intracellular 
domain (green line).  
 
The overall goal of this project was to investigate the transcriptional 
regulation of TMIGD1 in the hopes of contributing to a better understanding of 
the mechanisms that lead to the downregulation of TMIGD1 in human renal 
cancer. In particular, the specific aims of this project were: (A) to determine 
whether the known transcription factors that are implicated in renal cancer 
tumorigenesis regulate TMIGD1 promoter activity, including pVHL, HIF1α, 
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HIF2α, APC, and β-catenin, using a GPF reporter assay and (B) to test the role of 
the transcription factor C/EBPβ in the regulation of the TMIGD1 promoter.  
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METHODS 
Antibodies and Reagents 
Rabbit polyclonal anti-PLCγ antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-FLAG antibody was 
purchased from Agilent Technologies (Santa Clara, CA). Plasmids for VHL, APC, 
HIF1α, HIF2α, β-catenin, C/EBPβ/LIP, and C/EBPβ/LAP-FLAG were 
purchased from Addgene (Cambridge, MA).  
The promoter of TMIGD1 (1.24 kb) was PCR amplified from mRNA 
derived from human renal epithelial cells and cloned into pHAGE-GFP reporter 
vector (kindly provided by Dr. George Murphy, Boston University). The 1.24kb 
TMIGD1 promoter was used as a template to create additional truncated forms 
of the TMIGD1 promoter. All the constructs were sequenced to confirm their 
sequence identities (courtesy of Rosana Meyer).  
 
Cell Culture 
HEK-293T cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% FBS and 50 units/mL of penicillin and streptomycin. 
Cells were allowed to grow in a 5% CO2, humidified, 37°C incubator.  
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Transient Transfections 
Approximately 18 hours prior to transfection, 293T cells were plated onto 
60mm x 15mm tissue culture dishes. The 293T cells were transfected when at 
nearly 60-80% confluence. For each plate, the appropriate plasmids and PEI were 
added in a 1µg DNA: 3µL PEI ratio to 400µL of serum-free DMEM and incubated 
for 15 minutes. After incubation with PEI, plasmids were added drop-wise to 
plates of 293T cells in 2mL of serum-free DMEM. Plates were incubated in a 5% 
CO2, humidified, 37°C incubator for 6 hours after which 2mL of DMEM 
containing 10% FBS and 50 units/ml of penicillin and streptomycin were added 
to each plate. The media in each plate was replaced with DMEM containing 10% 
FBS and 50 units/ml of penicillin and streptomycin 24 hours after transfection.  
For initial transfections to test the effects of pVHL, HIF1α, HIF2α, and 
APC, a stable cell line of 293T cells expressing full length TMIGD1 promoter 
cloned into a GFP reporter plasmid were used. Cells were plated on 60mm x 
15mm cell culture dishes and transfected once they were 60-80% confluent. In 
preparation for transfection, 3µg of the appropriate plasmid were added along 
with 9µL of PEI to 400µL of serum-free DMEM and allowed to incubate for 15 
minutes after which the mixture was added drop-wise to the plates of 293T cells 
in 2mL of serum-free DMEM. The plates were incubated in a 5% CO2, 
humidified, 37°C incubator for 6 hours. This was followed by the addition of 
2mL of DMEM containing 10% FBS and 50 units/ml of penicillin and 
streptomycin to each plate. After 24 hours, the media in each plate was replaced 
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with 4mL of DMEM containing 10% FBS and 50 units/ml of penicillin and 
streptomycin.  
 
FACS Analysis 
To prepare cells for FACS analysis, transfected 293T cells were trypsinized 
and re-suspended in Phosphate Buffered Saline (PBS) and subsequently 
subjected to FACS analysis to quantify GFP expression. 
 
Western Blot Analysis 
Following FACS analysis, the transfected 293T cells were centrifuged at 
1800 rpm for 10 minutes. The supernatant was aspirated and the cell-containing 
pellet was lysed in EB lysis buffer [10mM Tris-HCl/10% Glycerol/5mM EDTA 
(pH7.4)/50mM NaCl/50mM NaF/1% Triton X-100/1mM phenylmethylsylfonyl 
fluoride/2mM sodium orthovanadate/aprotinin (20mg/ml)]. Following lysis, 
cells were centrifuged at 12000 rpm in eppendorf tubes at 4°C for 15 minutes. 
Following centrifugation, 5X sample buffer [bromophenol blue 
(0.25%)/dithiothreeitol (DTT)(0.5M)/glycerol (50%), sodium dodecyl sulfate 
(SDS)(10%)/Tris-Cl (0.25M, pH 6.8)] was added to each cell lysate. Next, samples 
were denatured for 5 minutes at 95-98°C. Cell lysate samples were run through 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by transfer to 
polyvinylidene difluoride (PVDF) membranes. PVDF membranes were then 
tagged with antibodies specific to the protein of interest. The primary antibodies 
used were rabbit polyclonal anti-PLCγ1 diluted to a concentration of 1:5000 in 
	  18 
10% bovine serum albumin and mouse polyclonal anti-Flag antibody diluted to a 
concentration of 1:2500 in 10% bovine serum albumin. Secondary antibodies used 
were anti-mouse and anti-rabbit both diluted to a concentration of 1:10,000 in 
non-fat milk containing tween-20. Secondary antibodies, conjugated to 
horseradish peroxidase (HRP), were used to visualize protein bands using 
enhanced chemiluminescence.  
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RESULTS 
 
Characterization of the TMIGD1 Promoter 
 The TMIGD1 promoter was recently cloned in our laboratory from human 
kidney epithelial (HK2) cells (Arafa et al., 2015). Initial data indicated that 5’ 
truncation of the TMIGD1 promoter significantly affects the promoter’s activity, 
as indicated by a Z-Green reporter gene, a sensitive GFP mutant (herein referred 
to as GFP) (contributed by Rosana Meyer, unpublished data). The full-length 
promoter (1.24kb) displayed very low (1.8%) GFP expression, which indicates 
low promoter activation as less GFP protein is produced (Figure 3). Deletion 
from the 5’ end up to 189 bases upstream of the initiation start site (-1 to -189) 
resulted in an increase promoter activity as GFP expression was increased to 
21.8% (Figure 3). As the promoter was further truncated such that only the 90 
bases upstream of the transcription start site are present (-1 to -90), the GFP 
expression was increased further to 37.6% (Figure 3). Maximum fluorescence is 
consistently observed with this (-1 to -90) truncation. These differences are 
visually notable, have been confirmed by FACS analysis, and suggest that 
perhaps the promoter sequences that were removed upon truncation contain 
elements that are able to bind inhibitory factors that prevent the full activation of 
the promoter. When the promoter is truncated, these binding sites may be 
removed and thus there is an increase in GFP expression. This also implies that 
the shorter promoter lengths may still contain binding sites for activating factors 
that allows for increased promoter activity and GFP transcription. Furthermore, 
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given that maximum GFP expression is observed with the -1 to -90 truncated 
TMIGD1 promoter, evidence suggests that this segment of the promoter contains 
regions that are necessary for maximum activity. This data informed the 
investigation into the transcriptional regulation of TMIGD1.  
 
Figure 3: Activity of the TMIGD1 Promoter. (A) A schematic of the full-length 
TMIGD1 promoter plasmid as well as two truncated plasmids, which were 
cloned into GFP reporter vectors. Putative C/EBPβ binding sites are also 
highlighted. (B) Images taken under a fluorescent microscope (20X). (C) FACS 
analysis data for GFP quantification (Meyer et al., 2017, unpublished data).  
 
Effect of pVHL, APC, HIF1α , HIF2α , and β-catenin on TMIGD1 Promoter 
Activity 
 To test the effects of the transcription factors commonly implicated in 
renal cancer, 293T cells that expressed the full-length TMIGD1 promoter 
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upstream of a GFP mutant, known as Z-Green, were transiently transfected with 
individual plasmids of the proteins of interest. The transient transfections with 
VHL, APC, HIF1α, and HIF2α show the same minimal fluorescence that is 
observed in 293T cells expressing the full-length promoter alone (Figure 4). The 
experiment was repeated with a co-transfection of the full-length TMIGD1 
promoter plasmid construct and APC, VHL, or β-catenin. The results of this 
transient co-transfection also showed little differences in the fluorescence of the 
cells as observed by fluorescent microscopy (Figure 5). These results suggest that 
VHL, APC, HIF1α, HIF2α, and β-catenin are not likely transcription factors 
involved in the transcriptional regulation of TMIGD1.  
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Figure 4: Effect of VHL, APC, HIF1α , and HIF2α  on the TMIGD1 promoter. 
The images above of 293 T cells expressing the full-length TMIGD1 promoter 
cloned into a GFP reporter vector, taken under fluorescent microscopy, indicate 
little differences in GFP expression between control and cells that were 
transfected with VHL, APC, HIF1α, or HIF2α.  
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 Figure 5: Effect of VHL, APC, β-catenin on the TMIGD1 promoter. 293T cells 
were co-transfected with the full-length TMIGD1 promoter cloned into a GFP 
reporter vector and VHL, APC, or β-catenin plasmids. Images were taken under 
fluorescent microscopy. Images indicate little difference in fluorescence between 
control and cells transfected with APC, β-catenin, and VHL.  
 
C/EBPβ  regulates the TMIGD1 promoter 
 Our initial bioinformatics analysis identified the presence of multiple 
putative C/EBPβ binding sites on the TMIGD1 promoter (Figure 3A), suggesting 
a possible role for C/EBP! in the regulation of TMIGD1 promoter activity. To 
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test the effects of C/EBP! on the TMIGD1 promoter, both the transcriptionally 
inactive (LIP) and transcriptionally active (LAP) forms of C/EBPβ were tested. If 
C/EBP! is able to bind to the TMIGD1 promoter, it is predicted that expression 
of LIP should inhibit promoter activity, given that it is a dominant negative form 
of C/EBP!, while expression of LAP is expected to have a stimulatory effect. 
The effect of the dominant negative C/EBPβ/LIP was tested using a co-
transfection of several promoter truncations and the LIP plasmid. LIP was 
consistently seen to have an inhibitory effect on the promoter activity of 
TMIGD1, as indicated by GFP expression (Figures 6, 7, 8). Observations and 
FACS analysis indicate that LIP is able to inhibit GFP expression in the -1 to -595 
promoter length by a 62.75% reduction. When LIP is co-transfected with the -189 
to -595 promoter length into 293T cells, a 49.8% reduction in GFP expression is 
observed. Finally, when LIP is co-transfected with the -1 to -189 promoter length, 
a 40.9% reduction in GFP expression is observed.  
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Figure 6: Effect of C/EBPβ/LIP on the TMIGD1 promoter (-1 to -595). (A) 293T 
cells were co-transfected with -1 to -595 TMIGD1 promoter cloned into GFP 
reporter vectors alone (control) and with C/EBPβ/LIP. Images were taken under 
fluorescent microscopy. (B) FACS analysis data of GFP quantification. 
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Figure 7: Effect of C/EBPβ/LIP on the TMIGD1 promoter (-189 to -595). (A) 
293T cells were co-transfected with -189 to -595 TMIGD1 promoter cloned into 
GFP reporter vectors alone (control) and with C/EBPβ/LIP. Images were taken 
under fluorescent microscopy. (B) FACS analysis data of GFP quantification. 
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Figure 8: Effect of C/EBPβ/LIP on the TMIGD1 promoter (-1 to -189). (A) 293T 
cells were co-transfected with -1 to -189 TMIGD1 promoter cloned into GFP 
reporter vectors alone (control) and with C/EBPβ/LIP. Images were taken under 
fluorescent microscopy. (B) FACS analysis data of GFP quantification. 
 
 Given that LIP is a dominant negative form of C/EBP!/LAP and that LIP 
had an inhibitory effect on promoter activity, the effect of LAP on the TMIGD1 
promoter was tested next. Focusing on the full-length promoter, as this is the 
phenotype presumably found under normal physiological conditions, 293T cells 
were co-transfected with the full-length TMIGD1 promoter cloned into a GFP 
reporter vector alone and with LAP-FLAG. The results of this experiment are 
displayed in Figure 9. These cells were lysed and successful transfection of 
	  28 
C/EBPβ/LAP-FLAG into these 293T cells was demonstrated via Western blot 
(Figure 10). Western blotting demonstrates that C/EBPβ/LAP-FLAG was indeed 
successfully transfected into the 293T cells and relative amounts of LAP-FLAG 
are shown (Figure 10).  The data suggests that when LAP-FLAG is transfected in 
a more moderate amount, as in Trials 2 and 3, LAP activates the full length 
TMIGD1 promoter, as indicated by GFP expression. In Trial 2, there was a 40.3% 
increase in GFP expression (Figure 9). In Trial 3, there was a 91.7% increase in 
GFP expression (Figure 9). However, when there was a relatively high amount of 
LAP-FLAG transfected into 293T cells, as in Trial 1, only a 14.3% reduction in 
GFP expression was observed (Figure 9). This data suggests that at levels closer 
to physiological conditions, LAP activates the TMIGD1 promoter; however, at 
levels beyond a specific threshold, LAP may begin to have an inhibitory effect. 
Given the stimulatory effect of C/EBPβ/LAP on the full-length TMIGD1 
promoter, it was predicted that the promoter would be refractory to 
C/EBPβ/LAP once the predicted C/EBPβ binding sites are removed. To test this, 
293T cells were transfected with the  -1 to -90 truncated TMIGD1 promoter alone 
and with C/EBPβ/LAP (Figure 11). The results indicate that once the C/EBPβ 
binding sites are removed, there is no significant change in promoter activity, as 
indicated by a mere a 5.1% reduction in GFP expression (Figure 11).  
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Figure 9: Effect of C/EBPβ/LAP on the TMIGD1 Promoter. 293T cells were co-
transfected with full-length TMIGD1 promoter cloned into GFP reporter vectors 
alone and with C/EBPβ/LAP-FLAG. The experiment was carried out in 
triplicate (Trials 1, 2, 3). Images were taken under a fluorescent microscope and 
FACS analysis was carried out to quantify GFP expression. 
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Figure 10: C/EBPβ  /LAP expression in transfected cells. Western blot of 293T 
cells transfected with the full-length TMIGD1 promoter cloned into GFP reporter 
vectors alone and with C/EBPβ/LAP-FLAG. PLCγ was used as the loading 
control and the membrane was incubated for one hour with 1:5000 rabbit anti- 
PLCγ1 antibody. The membrane was also incubated for one hour with 1:2500 
mouse monoclonal anti-FLAG antibody in order to detected FLAG-tagged 
C/EBPβ/LAP. 
 
	  31 
 Figure 11: Effect of C/EBPβ/LAP on the truncated TMIGD1 promoter. A) 293T 
cells were co-transfected with -1 to -90 TMIGD1 promoter cloned into GFP 
reporter vectors alone (control) and with C/EBPβ/LAP. Images were taken 
under fluorescent microscopy. (B) FACS analysis data of GFP quantification. 
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DISCUSSION 
 
 The aim of this study was to investigate the transcriptional regulation of 
TMIGD1, a member of the immunoglobulin-like cell adhesion molecules that is 
downregulated in human renal cancers (Meyer et al., 2017, unpublished data not 
shown). Specifically, the effects of the commonly implicated proteins in renal 
cancer tumorigenesis, namely pVHL, HIF1α, HIF2α, APC and β-catenin, in the 
transcriptional regulation of TMIGD1 were studied using a GFP-reporter assay. 
In addition, guided by bioinformatics data that suggested the presence of 
putative C/EBPβ binding sites within the TMIGD1 promoter (Figure 3A) as well 
as literature that implicates the C/EBPβ/LIP to C/EBPβ/LAP ratio in 
tumorigenesis, the effects of C/EBPβ on the transcriptional activation of the 
TMIGD1 promoter were also studied (Bégay et al., 2015; Zahnow et al., 2001).  
The investigation of TMIGD1 transcriptional regulation established 
several key points. First, the effects of pVHL, APC, HIF1α, HIF2α, and β-catenin 
on the TMIGD1 promoter were studied. It was demonstrated that despite their 
relevance in the genetics of renal cancer, pVHL, APC, HIF1α, HIF2α, and β-
catenin do not appear to be directly involved in the transcriptional regulation of 
TMIGD1. However, this does not eliminate the possibility that these proteins and 
transcription factors might regulate TMIGD1 expression at post-transcriptional 
levels.  
This investigation also demonstrated that C/EBPβ/LAP has a stimulatory 
effect on the full-length TMIGD1 promoter, as demonstrated by an increase in 
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GFP expression. The effect of LAP on the TMIGD1 promoter was tested in an 
experiment in which 293T cells were co-transfected with the promoter plasmid 
alone and with LAP-FLAG plasmid. The experimental results indicate that 
C/EBPβ/LAP can activate the TMIGD1 promoter, as indicated by GFP 
expression. Interestingly, these results also suggest that perhaps C/EBPβ/LAP’s 
ability to activate the TMIGD1 promoter depends on a specific C/EBPβ/LAP 
threshold. When there is a relatively large amount of LAP-FLAG transfected into 
293T cells, a slight reduction in the promoter activation was observed. 
Meanwhile, when the levels of LAP-FLAG transfected into the 293T cells were 
relatively closer to physiological levels, an increase in promoter activation and 
GFP expression was observed. It is possible that LAP functions such that above a 
certain threshold concentration it begins to have an inhibitory effect by out-
competing other transcription factors that would act as activators, however more 
research is required to address this. In addition, once the predicted C/EBPβ 
binding sites on the promoter were removed, the TMIGD1 promoter’s activity 
was not significantly affected by C/EBPβ/LAP. Co-transfection of LAP-FLAG 
and the TMIGD1 promoter containing only the 90 bases upstream of the 
initiation start site (-1 to -90) indicate minimal changes in GFP expression, and 
thus minimal changes in promoter activity, when compared to control. This 
suggests that the effect of C/EBPβ/LAP on the TMIGD1 promoter activity is 
dependent on the presence of the putative C/EBPβ binding sites. 
The effect of C/EBPβ/LIP, the dominant negative form of C/EBPβ/LAP, 
on TMIGD1 promoter activity was also demonstrated. As the dominant negative 
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form, LIP was expected to have an inhibitory effect on the TMIGD1 promoter. 
Given the normally low promoter activity of TMIGD1 full-length promoter 
(Figure 3), it was difficult to study the effect of C/EBPβ/LIP on GFP expression 
under these conditions, thus several promoter lengths with reasonable baseline 
activity were selected for this study. According to GFP expression data obtained 
from FACS analysis, LIP seems to have an inhibitory effect on the promoter 
activity of several of the TMIGD1 truncations. This observed effect suggests that 
the DNA-binding domain of C/EBPβ/LIP, which is synonymous to the DNA-
binding domain of C/EBPβ/LAP, can perhaps recognize and bind to the 
predicted sites on the TMIGD1 promoter. As the dominant negative form, LIP 
may bind to the C/EBPβ binding sites on the promoter and because it lacks 
transactivation domains, it is able to prevent the activation of the TMIGD1 
promoter. 
Given these observed effects of C/EBPβ/LIP and C/EBPβ/LAP on the 
TMIGD1 promoter activity, further investigation into the specific role of C/EBPβ 
in the transcriptional regulation is warranted. Further studies could specifically 
investigate the effect of introduction or knockdown of C/EBPβ on the TMIGD1 
protein expression in renal cells. Studies to determine whether re-introduction of 
C/EBPβ/LAP is able to increase TMIGD1 expression in renal cancer cells that 
have very low expression of this adhesion molecule could also yield valuable 
insight into the transcriptional regulation of TMIGD1. In addition, given the 
homology in the DNA-binding domains of the C/EBP family members, 
investigation into other possible C/EBP family members’ effects on the TMIGD1 
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promoter activity and on TMIGD1 expression may be beneficial to the 
elucidation of the transcriptional regulation of TMIGD1 (Tsukada et al., 2011). 
The importance of understanding C/EBPβ’s role in the transcriptional 
regulation of TMIGD1 lies in the possibility that TMIGD1 may be a tumor 
suppressor. Thus the ability to alter TMIGD1 expression using our 
understanding of its transcriptional regulation, perhaps by targeting 
transcription factors involved in the activation or suppression of its expression, 
might present itself as a specific method in the treatment of renal cell carcinomas. 
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